Tuberculosis screening in high human immunodeficiency virus prevalence settings: Turning promise into reality

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 9, 2013, Pages 1125-1138

  Corbett, E L ^a,b   MacPherson, P ^b,c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b MALAWI LIVERPOOL WELLCOME TRUST CLINICAL RESEARCH PROGRAMME   (Malawi)

^c LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Case finding; Community; Disease control; Health facility; HIV; Prevention; Screening; Tuberculosis

Indexed keywords

ISONIAZID; LIPOARABINOMANNAN;

ARTICLE; ASYMPTOMATIC INFECTION; BACTERIUM CULTURE; COMMUNITY ASSESSMENT; CONTACT EXAMINATION; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE POLICY; HEALTH EDUCATION; HIGH RISK POPULATION; HIV TEST; HOUSEHOLD; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MASS SCREENING; MATHEMATICAL MODEL; MORBIDITY; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; RESEARCH PRIORITY; SENSITIVITY AND SPECIFICITY; SYMPTOM ASSESSMENT; THORAX RADIOGRAPHY; TUBERCULOSIS; TUBERCULOSIS CONTROL; VIRUS TRANSMISSION;

EID: 84882949445     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0117     Document Type: Article

References (111)

1. World Health Organization. Global tuberculosis report. WHO/HTM/TB/2012.6. Geneva, Switzerland: WHO, 2012.
2. Gandhi N R, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
3. Vella V, Racalbuto V, Guerra R, et al. Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting. Int J Tuberc Lung Dis 2011; 15: 1170-1175.
4. Cox J A, Lukande R L, Lucas S, Nelson A M, Van Marck E, Colebunders R. Autopsy causes of death in HIV-positive individuals in sub-Saharan Africa and correlation with clinical diagnoses. AIDS Rev 2010; 12: 183-194.
5. Cohen T, Murray M, Wallengren K, Alvarez G G, Samuel E Y, Wilson D. The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in Kwa Zulu-Natal, South Africa: a postmortem study. PLoS Med 2010; 7: e1000296.
6. Ayles H, the ZAMSTAR Study Team. A household-based HIV and TB intervention increases HIV testing in households and reduces prevalence of TB at the community level: the ZAMSTAR Community Randomized Trial. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012, Seattle, WA, USA. [Abstract 149bLB]
7. Corbett E L, Bandason T, Duong T, et al. Comparison of two active case-finding strategies for community-based diagnosis of symptomatic smear-positive tuberculosis and control of infectious tuberculosis in Harare, Zimbabwe (DETECTB): a clusterrandomised trial. Lancet 2010; 376: 1244-1253.
8. Churchyard G J, Fielding K, Roux S, et al. Twelve-monthly versus six-monthly radiological screening for active case-finding of tuberculosis: a randomised controlled trial. Thorax 2011; 66: 134-139.
9. O'Grady J, Bates M, Chilukutu L, et al. Evaluation of the Xpert MTB/RIF assay at a tertiary care referral hospital in a setting where tuberculosis and HIV infection are highly endemic. Clin Infect Dis 2012; 55: 1171-1178.
10. Churchyard G J, Fielding K L, Lewis J J, et al. Clusterr andomised trial of community-wide isoniazid preventive therapy for tuberculosis control among gold miners in South Africa: the Thibela TB study. 19th Conference on Retroviruses and Opportunistic Infections, 5-8 March 2012. Seattle, WA, USA: CROI, 2012.
11. Suthar A B, Lawn S D, del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012; 9: e1001270.
12. Middelkoop K, Bekker L G, Myer L, et al. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med 2010; 182: 1080-1085.
13. Granich R, Williams B, Montaner J. Fifteen million people on antiretroviral treatment by 2015: treatment as prevention. Curr Opin HIV AIDS 2013; 8: 41-49.
14. Sabapathy K, Van den Bergh R, Fidler S, Hayes R, Ford N. Uptake of home-based voluntary HIV testing in sub-Saharan Africa: a systematic review and meta-analysis. PLoS Med 2012; 9: e1001351.
15. Stop TB Partnership/The Global Fund/World Health Organization. Priorities in operational research to improve tuberculosis care and control. Geneva, Switzerland: WHO, 2012.
16. World Health Organization. Early detection of tuberculosis. An overview of approaches, guidelines and tools. WHO/HTM/STB/PSI/2011.21 Geneva, Switzerland: WHO, 2011.
17. World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, Switzerland: WHO, 2011.
18. Getahun H, Kittikraisak W, Heilig C M, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011; 8: e1000391.
19. den Boon S, White N W, van Lill S W P, et al. An evaluation of symptom and chest radiographic screening in tuberculosis prevalence surveys. Int J Tuberc Lung Dis 2006; 10: 876-882.
20. Wood R, Middelkoop K, Myer L, et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007; 175: 87-93.
21. Corbett E L, Bandason T, Cheung Y-B, et al. Prevalent infectious tuberculosis in Harare, Zimbabwe: burden, risk factors and implications for control. Int J Tuberc Lung Dis 2009; 13: 1231-1237.
22. Ayles H, Schaap A, Nota A, et al. Prevalence of tuberculosis, HIV and respiratory symptoms in two Zambian communities: implications for tuberculosis control in the era of HIV. PLoS ONE 2009; 4: e5602.
23. van't Hoog A H, Laserson K F, Githui W A, et al. High prevalence of pulmonary tuberculosis and inadequate case finding in rural western Kenya. Am J Respir Crit Care Med 2011; 183: 1245-1253.
24. Shapiro A E, Variava E, Rakgokong M H, et al. Communitybased targeted case finding for tuberculosis and HIV in household contacts of patients with tuberculosis in South Africa. Am J Respir Crit Care Med 2012; 185: 1110-1116.
25. Corbett E L, Charalambous S, Moloi V M, et al. Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners. Am J Respir Crit Care Med 2004; 170: 673-679.
26. Corbett E L, Bandason T, Cheung Y B, et al. Epidemiology of tuberculosis in a high HIV prevalence population provided with enhanced diagnosis of symptomatic disease. PLoS Med 2007; 4: e22.
27. Hoffmann C J, Variava E, Rakgokong M, et al. High prevalence of pulmonary tuberculosis but low sensitivity of symptom screening among HIV-infected pregnant women in South Africa. PLoS ONE 2013; 8: e62211.
28. Shah S, Demissie M, Lambert L, et al. Intensified tuberculosis case finding among HIV-infected persons from a voluntary counseling and testing center in Addis Ababa, Ethiopia. J A cquir Immune Defic Syndr 2009; 50: 537-545.
29. Lawn S D, Edwards D J, Kranzer K, Vogt M, Bekker L G, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 2009; 23: 1875-1880.
30. Cain K P, McCarthy K D, Heilig C M, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 2010; 362: 707-716.
31. Bassett I V, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010; 51: 823-829.
32. Fourie P B, Gatner E M, Glatthaar E, Kleeberg H H. Follow-up tuberculosis prevalence survey of Transkei. Tubercle 1980; 61: 71-79.
33. Roelsgaard E, Iversen E, Blocher C. Tuberculosis in tropical Africa: an epidemiological study. Bull World Health Organ 1964; 30: 459-518.
34. Howard A A, Gasana M, Getahun H, et al. PEPFAR support for the scaling up of collaborative TB/HIV activities. J Acquir Immune Defic Syndr 2012; 60 (Suppl 3): S136-S144.
35. Lönnroth K, Jaramillo E, Williams B G, Dye C, Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 2009; 68: 2240-2246.
36. Dowdy D W, Basu S, Andrews J R. Is passive diagnosis enough? The impact of subclinical disease on diagnostic strategies for tuberculosis. Am J Respir Crit Care Med 2013; 187: 543-551.
37. Bedell R A, Anderson S T, van Lettow M, et al. High prevalence of tuberculosis and serious bloodstream infections in ambulatory individuals presenting for antiretroviral therapy in Malawi. PLoS ONE 2012; 7: e39347.
38. Kranzer K, Houben R M G J, Glynn J R, Bekker L G, Wood R, Lawn S D. Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 93-102.
39. Kufa T, Mngomezulu V, Charalambous S, et al. Undiagnosed tuberculosis among HIV clinic attendees: association with antiretroviral therapy and implications for intensified case finding, isoniazid preventive therapy, and infection control. J Acquir Immune Defic Syndr 2012; 60: 22-28.
40. Fox G J, Dobler C C, Marks G B. Active case finding in contacts of people with tuberculosis. Cochrane Database Syst Rev (Online) 2011; (9): CD008477.
41. Kranzer K, Lawn S D, Meyer-Rath G, et al. Feasibility, yield, and cost of active tuberculosis case finding linked to a mobile HIV service in Cape Town, South Africa: a cross-sectional study. PLoS Med 2012; 9: e1001281.
42. Sekandi J N, Neuhauser D, Smyth K, Whalen C C. Active case finding of undetected tuberculosis among chronic coughers in a slum setting in Kampala, Uganda. Int J Tuberc Lung Dis 2009; 13: 508-513.
43. The ZAMSTAR Study Team. The ZAMSTAR Study-c ommunity and household interventions to reduce tuberculosis in Zambian and South African communities. 42nd World Conference on Lung Health of the International Union Against Tuberculosis and Lung Disease, Lille, France, 26-30 October 2011.
44. Kranzer K, Afnan-Holmes H, Tomlin K, et al. The benefits to communities and individuals of screening for active tuberculosis disease: a systematic review. Int J Tuberc Lung Dis 2013; 17: 432-446.
45. Lönnroth K, Corbett E, Golub J, et al. Systematic screening for active tuberculosis: rationale, definitions and key considerations. Int J Tuberc Lung Dis 2013; 17: 289-298.
46. Cobelens F, van den Hof S, Pai M, Squire S B, Ramsay A, Kimerling M E. Which new diagnostics for tuberculosis, and when? J Infect Dis 2012; 205 (Suppl 2): S191-S198.
47. McNerney R, Maeurer M, Abubakar I, et al. Tuberculosis d iagnostics and biomarkers: needs, challenges, recent advances, and opportunities. J Infect Dis 2012; 205 (Suppl 2): S147-S158.
48. van't Hoog A H. Sensitivity and specificity of different TB screening tools and approaches: a systematic review. 43rd Union World Conference on Lung Health, Kuala Lumpur, Malaysia, 13-17 November 2012.
49. Dorman S E, Chihota V N, Lewis J J, et al. Performance characteristics of the Cepheid Xpert MTB/RIF test in a tuberculosis prevalence survey. PLoS ONE 2012; 7: e43307.
50. Lawn S D, Brooks S V, Kranzer K, et al. Screening for HIVa ssociated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011; 8: e1001067.
51. Ntinginya E N, Squire S B, Millington K A, et al. Performance of the Xpert® MTB/RIF assay in an active case-finding strategy: a pilot study from Tanzania. Int J Tuberc Lung Dis 2012; 16: 1468-1470.
52. Lawn S D, Kerkhoff A D, Vogt M, Ghebrekristos Y, Whitelaw A, Wood R. Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin Infect Dis 2012; 54: 1071-1079.
53. Monkongdee P, McCarthy K D, Cain K P, et al. Yield of acidfast smear and mycobacterial culture for tuberculosis diagnosis in people with HIV. Am J Respir Crit Care Med 2009; 180: 903-908.
54. Walley J, Kunutsor S, Evans M, et al. Validation in Uganda of the new WHO diagnostic algorithm for smear-negative pulmonary tuberculosis in HIV prevalent settings. J Acquir Immune Defic Syndr 2011; 57: 93-100.
55. Andrews J R, Lawn S D, Rusu C, et al. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS 2012; 26: 987-995.
56. Oni T, Burke R, Tsekela R, et al. High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening. Thorax 2011; 66: 669-673.
57. Meintjes G, Wilkinson R J, Morroni C, et al. Randomized p lacebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010; 24: 2381-2390.
58. Nicholas S, Sabapathy K, Ferreyra C, Varaine F, Pujades-Rodríguez M. Incidence of tuberculosis in HIV-infected patients before and after starting combined antiretroviral therapy in 8 sub-Saharan African HIV programs. J Acquir Immune Defic Syndr 2011; 57: 311-318.
59. Zar H J, Cotton M F, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 2007; 334: 136.
60. Balcells M E, Thomas S L, Godfrey-Faussett P, Grant A D. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006; 12: 744-751.
61. van Halsema C L, Fielding K L, Chihota V N, et al. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS 2010; 24: 1051-1055.
62. Godfrey-Faussett P, Sonnenberg P, Shearer S C, et al. Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet 2000; 356: 1066-1071.
63. Hogeweg L, Mol C, de Jong P A, Dawson R, Ayles H, van Ginneken B. Fusion of local and global detection systems to detect tuberculosis in chest radiographs. Medical image computing and computer-assisted intervention. Med Image Comput Comput Assist Interv 2010; 13 (Pt 3): 650-657.
64. Den Boon S, Bateman E D, Enarson D A, et al. Development and evaluation of a new chest radiograph reading and recording system for epidemiological surveys of tuberculosis and lung disease. Int J Tuberc Lung Dis 2005; 9: 1088-1096.
65. Story A, Aldridge R W, Abubakar I, et al. Active case finding for pulmonary tuberculosis using mobile digital chest radiography: an observational study. Int J Tuberc Lung Dis 2012; 16: 1461-1467.
66. van't Hoog A H, Meme H K, van Deutekom H, et al. High sensitivity of chest radiograph reading by clinical officers in a tuberculosis prevalence survey. Int J Tuberc Lung Dis 2011; 15: 1308-1314.
67. Churchyard G J, Kleinschmidt I, Corbett E L, Mulder D, De Cock K M. Mycobacterial disease in South African gold miners in the era of HIV infection. Int J Tuberc Lung Dis 1999; 3: 791-798.
68. World Health Organization. TB prevalence surveys: a handbook. WHO/HTM/TB/2010.17. Geneva, Switzerland: WHO, 2011.
69. Abubakar I, Stagg H R, Cohen T, et al. Controversies and unresolved issues in tuberculosis prevention and control: a lowburden-country perspective. J Infect Dis 2012; 205 (Suppl 2): S293-S300.
70. Dawson R, Masuka P, Edwards D J, et al. Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV. Int J Tuberc Lung Dis 2010; 14: 52-58.
71. Agizew T B, Arwady M A, Yoon J C, et al. Tuberculosis in a symptomatic HIV-infected adults with abnormal chest radiographs screened for tuberculosis prevention. Int J Tuberc Lung Dis 2010; 14: 45-51.
72. Mosimaneotsile B, Talbot E A, Moeti T L, et al. Value of chest radiography in a tuberculosis prevention programme for HIVinfected people, Botswana. Lancet 2003; 362: 1551-1552.
73. Samandari T, Bishai D, Luteijn M, et al. Costs and consequences of additional chest X-ray in a tuberculosis prevention program in Botswana. Am J Respir Crit Care Med 2010; 183: 1103-1111.
74. World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system: policy statement. Geneva, Switzerland: WHO, 2011.
75. Lawn S D, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013; 13: 349-361.
76. Menzies N A, Cohen T, Lin H H, Murray M, Salomon J A. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med 2012; 9: e1001347.
77. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med 2011; 8: e1001120.
78. Lawn S D, Kranzer K, Edwards D J, McNally M, Bekker L G, Wood R. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 2010; 24: 1323-1328.
79. Lawn S D, Harries A D, Meintjes G, Getahun H, Havlir D V, Wood R. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2012; 26: 2121-2133.
80. MacPherson P, Dimairo M, Bandason T, et al. Risk factors for mortality in smear-negative tuberculosis suspects: a cohort study in Harare, Zimbabwe. Int J Tuberc Lung Dis 2011; 15: 1390-1396.
81. Kyeyune R, den Boon S, Cattamanchi A, et al. Causes of early mortality in HIV-infected TB suspects in an East African referral hospital. J Acquir Immune Defic Syndr 2010; 55: 446-450.
82. Stuart-Clark H, Vorajee N, Zuma S, et al. Twelve-month outcomes of patients admitted to the acute general medical service at Groote Schuur Hospital. S Afr Med J 2012; 102: 549-553.
83. Westreich D, Fox M P, Van Rie A, Maskew M. Prevalent tuberculosis and mortality among HAART initiators. AIDS 2012; 26: 770-773.
84. Williams B G, Granich R, De Cock K M, Glaziou P, Sharma A, Dye C. Antiretroviral therapy for tuberculosis control in nine African countries. Proc Natl Acad Sci USA 2010; 107: 19485-19489.
85. Granich R, Gupta S, Suthar A B, et al. Antiretroviral therapy in prevention of HIV and TB: update on current research efforts. Curr HIV Res 2011; 9: 446-469.
86. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007; 369: 2042-2049.
87. Dimairo M, MacPherson P, Bandason T, et al. The risk and timing of tuberculosis diagnosed in smear-negative TB suspects: a 12-month cohort study in Harare, Zimbabwe. PLoS ONE 2010; 5: e11849.
88. Golub J E, Mohan C I, Comstock G W, Chaisson R E. Active case finding of tuberculosis: historical perspective and future prospects. Int J Tuberc Lung Dis 2005; 9: 1183-1203.
89. Lewis J J, Charalambous S, Day J H, et al. HIV infection does not affect active case finding of tuberculosis in South African gold miners. Am J Respir Crit Care Med 2009; 180: 1271-1278.
90. Datiko D G, Lindtjorn B. Health extension workers improve tuberculosis case detection and treatment success in southern Ethiopia: a community randomized trial. PLoS ONE 2009; 4: e5443.
91. Lugada E, Millar D, Haskew J, et al. Rapid implementation of an integrated large-scale HIV counseling and testing, malaria, and diarrhea prevention campaign in rural Kenya. PLoS ONE 2010; 5: e12435.
92. Simwaka B N, Theobald S, Willets A, et al. Acceptability and effectiveness of the storekeeper-based TB referral system for TB suspects in sub-districts of Lilongwe in Malawi. PLoS ONE 2012; 7: e39746.
93. Suthar A B, Klinkenberg E, Ramsay A, et al. Community-based multi-disease prevention campaigns for controlling human i mmunodeficiency virus-associated tuberculosis. Int J Tuberc Lung Dis 2012; 16: 430-436.
94. Morrison J, Pai M, Hopewell P C. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8: 359-368.
95. Kennedy C E, Fonner V A, Sweat M D, Okero F A, Baggaley R, O'Reilly K R. Provider-initiated HIV testing and counseling in low-and middle-income countries: a systematic review. AIDS Behav 2013; 17: 1571-1590.
96. World Health Organization. WHO policy on TB infection control in health-care facilities, congregate settings and households. WHO/HTM/TB/2009.419. Geneva, Switzerland: WHO, 2009.
97. Khan A J, Khowaja S, Khan F S, et al. Engaging the private sector to increase tuberculosis case detection: an impact evaluation study. Lancet Infect Dis 2012; 12: 608-616.
98. Floyd K, Pantoja A. Financial resources required for tuberculosis control to achieve global targets set for 2015. Bull World Health Organ 2008; 86: 568-576.
99. Dodd P J, White R G, Corbett E L. Periodic active case finding for TB: when to look? PLoS ONE 2011; 6: e29130.
100. Dowdy D W, Chaisson R E. The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection. Bull World Health Organ 2009; 87: 296-304.
101. Dye C, Bassili A, Bierrenbach A L, et al. Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect Dis 2008; 8: 233-243.
102. Medical Research Council. Developing and evaluating complex interventions. London, UK: MRC, 2013. www.mrc.ac. uk/ complexinterventionsguidance Accessed June 2013.
103. Stop TB Partnership, World Health Organization. TB impact measurement policy and recommendations for how to assess the epidemiological burden of TB and the impact of TB control. Geneva, Switzerland: WHO, 2010.
104. Dowdy D W, Gounder C R, Corbett E L, Ngwira L G, Chaisson R E, Merritt M W. The ethics of testing a test: randomized trials of the health impact of diagnostic tests for infectious diseases. Clin Infect Dis 2012; 55: 1522-1526.
105. Lin H H, Dowdy D, Dye C, Murray M, Cohen T. The impact of new tuberculosis diagnostics on transmission: why context matters. Bull World Health Organ 2012; 90: 739-747.
106. Demissie M, Zenebere B, Berhane Y, Lindtjorn B. A rapid survey to determine the prevalence of smear-positive tuberculosis in Addis Ababa. Int J Tuberc Lung Dis 2002; 6: 580-584.
107. Laga M, Piot P. Prevention of sexual transmission of HIV: real results, science progressing, societies remaining behind. AIDS 2012; 26: 1223-1229.
108. CDI Study Group. Community-directed interventions for priority health problems in Africa: results of a multicountry study. Bull World Health Organ 2010; 88: 509-518.
109. Squire S B, Ramsay A R C, van den Hof S, et al. Making innovations accessible to the poor through implementation research. Int J Tuberc Lung Dis 2011; 15: 862-870.
110. Moonen B, Cohen J M, Snow R W, et al. Operational strategies to achieve and maintain malaria elimination. Lancet 2010; 376: 1592-1603.
111. Dowdy D W, Golub J E, Chaisson R E, Saraceni V. Heterogeneity in tuberculosis transmission and the role of geographic hotspots in propagating epidemics. Proc Natl Acad Sci USA 2012; 109: 9557-9562.